Conclusions and Relevance: The current evidence underscores the potential of GLP-1 RAs as a novel therapeutic approach for certain psychiatric disorders, particularly alcohol-related disorders, depression, and autism-related food behaviors
In instances where food consumption is naturally reduced, supplements help safeguard against potential nutritional deficiencies without overcompensating with calories
To stay competitive, brands must deliver value through format innovation, functional benefits and relevance to evolving consumer needs
The same active ingredient powers Wegovy, which received FDA approval specifically for obesity treatment in 2021
As the insulinotropic capacity of GLP-1 is partially retained in diabetic humans, GLP-1-based treatments have been successfully developed
Other formulation parameters (e.g